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Summary. Nuclear medicine methods permit the in vivo
measurement of physiological and metabolic functions. For
this purpose metabolically active molecules are labelled with
radionuclides. After the injection, these radiopharmaceuti-
cals can be detected from outside the body with appropriate
detectors such as conventional gamma cameras, single pho-
ton emission computerized tomographs (SPECT), or positron
emission tomographs (PET). As with any application of ion-
izing radiation the benefits of nuclear medicine (the diagnosis
and treatment of disease) must be balanced against the risks
of the procedures. Risks in nuclear medicine are evaluated
through dosimetry, the calculation of the radiation dose es-
timates, in which the energy deposited by the radiation in
human tissues is quantitated. The first step of dosimetry is
the determination of the biodistribution, i.e. the spatial and
temporal distribution of the radiopharmaceutical within the
body. When a new radiopharmaceutical is introduced such
data are first derived from ex vivo experiments in animals.
Further evaluations of the biokinetics and dosimetry are car-
ried out via quantitative measurements in humans using the
nuclear medicine imaging equipment, applying whole-body
planar and tomographic methods. Based on the knowledge
of the biodistribution and using the framework introduced by
the MIRD committee as well as by the ICRP, the radiation
dose to single organs and to the total body can be calculated.
The purpose of this paper is to review methods for meas-
uring radiopharmaceutical biodistributions in humans and for
calculating the appropriate radiation dose quantities.
Introduction
Nuclear medicine provides diagnostic procedures which al-
low the investigation of physiological and metabolic func-
tions within the human body. For this purpose indicator
substances are administered to the patient by intravenous
injection, inhalation, or ingestion. The indicator substances
are labelled with radionuclides so that their distribution can
be determined by measuring the emitted radiation with ap-
propriate radiation-sensitive instruments. The measured data
are assembled into images such as planar scintigrams or to-
mographic images which are examined to obtain the medical
diagnosis. Only part of the activity emitted from the ra-
dionuclides reaches the radiation detectors whereas the rest
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is absorbed within the body. Radiation absorbed in the body
causes ionisation and excitation of atoms within the cells of
the body, possibly leading to cellular damage. If unrepaired,
this damage may lead to short term or long term negative
effects in the organism. The total energy deposited per unit
mass, called the absorbed dose, is generally accepted to be
proportional to these risks, and thus an appropriate quan-
tity for study of the possible effects of ionising radiation.
In order to estimate the absorbed dose the biodistribution,
i.e. the spatial and temporal quantitative distribution of the
administered radiopharmaceutical must be determined. For
this purpose, diagnostic instruments can be utilised directly
within or in addition to the diagnostic examination. If this is
not possible, biodistribution data must be derived from ap-
propriate animal models. Based on the biodistribution, the
dose to specific organs or to the whole-body is determined
by relating the radioactivity to the radiation energy deposited
throughout the body. The purpose of this paper is to review
methods for determining the biodistribution of radiopharma-
ceuticals and the radiation dose in nuclear medicine, espe-
cially in its tomographic applications SPECT and PET, and
to describe the framework for calculating dose estimates for
single organs and the whole-body from these biodistribution
data. This framework follows the recommendations of the
MIRD (Medical Internal Radiation Dose) committee as well
as those of the ICRP (International Commission of Radia-
tion Protection).
Biodistribution measurement of single photon
emitters
The first step to estimate the radiation dose related to
a newly developed radiopharmaceutical is to get knowledge
about the biodistribution. Because radiopharmaceuticals are
designed to image specific organs, quantitative uptake values
for these organs are known from previous pharmacokinetic
research. During the development of a radiopharmaceutical
it is of general interest to know the uptake also of organs
other than the organ of interest. The necessary measure-
ments are done commonly in rodents, especially mice and
rats. The percent of the injected activity found in individ-
ual organs is interpreted, usually through some extrapolation
method, to imply the biodistribution in humans. An example
of data obtained in such animal studies is given in Table 1
(taken from [1]).
Although biodistribution data obtained in animals are
very important for the introduction of a radiopharmaceutical
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Table 1. Biodistribution of 123I-α-O-methyltyrosine in mouse or-
gans in which significant activities were found (Schmidt et al. [1]).
(Units are (%) injected activity, decay-corrected.)
Time (min) Brain Pancreas Liver Kidneys Heart Thyroid.
2.00 0.85 4.85 8.49 21.69 0.87 0.03
5.00 1.27 7.53 10.28 36.63 1.18 0.05
10.00 2.42 14.49 13.51 63.78 1.67 0.07
20.00 1.85 6.87 9.25 34.37 1.00 0.06
40.00 0.73 2.72 3.76 15.52 0.40 0.03
60.00 0.63 2.40 3.17 16.62 0.43 0.01
100.00 0.56 2.70 2.58 10.87 0.27 0.01
one has to take into account that there may be consider-
able differences to the human biodistribution. Therefore, the
animal data have to be validated by quantitative measure-
ments of biodistribution in humans. Commercial radiophar-
maceuticals are practically exclusively developed for planar
scintigraphy and SPECT. Clinical SPECT is usually applied
as a qualitative imaging procedure. It is very rarely used
for quantitative measurements, which will not be discussed
here. The general method to obtain the biodistribution of sin-
gle photon emitting activity is conjugate whole-body imag-
ing, which combines anterior and posterior whole-body pro-
jections and which were already used before the introduction
of SPECT [2, 3]. This kind of scanning can conveniently
be performed by using double-headed SPECT cameras with
opposite gamma camera detectors and a whole-body scan-
ning capability (Fig. 1). The count rate of anterior (Na) and
posterior (Np) whole-body projections are combined pixel-
wise by calculating the geometric mean (GM) of opposite
pixels:
NGM = (Na Np)1/2 (1)
Equation (2) relates the geometric mean found at a specific
image pixel i to the activity Ai within a tube under this pixel:
Ai = G(NGM)i e(µ/2)Li µdi/2
sinh(µdi/2)
(2)
with
G: Constant of measurement device involving
efficiency etc,
Na, Np: Count rate at pixel i in anterior or posterior
view,
µ: Absorption coefficient at pixel i , L = l1+ l2
Li: Body thickness at pixel i ,
di: Organ thickness at pixel i .
In conventional planar scintigraphy, the unknown depth
of an organ is the decisive reason why scintigrams cannot
be evaluated quantitatively, i.e. they do not yield calibrated
values of radioactivity (kBq or nCi). Looking at a planar pro-
jection it is not possible to distinguish whether a decreased
low count rate is caused by a low activity within the or-
gan or by the organ depth, as much of the radiation emitted
from this source is absorbed by the overlaying tissue. Using
the geometric mean method the resulting data become inde-
pendent of the depth of a single organ within the body as
apparent from (2).
Fig. 1. Conjugate whole-body imaging with a dual-headed gamma-
camera system. The counts measured from anterior (NA) and posterior
(NP) are pixelwise geometrically averaged so that the resulting value is
independent of the depth of the activity source within the body.
Myers [4] showed that the quotient (µdi/2)/(sinh(µdi/2))
involving the organ thickness d is close to one, so that an ex-
act calculation of this term is not necessary. The attenuation
correction factor e(µ/2)L includes the unknown absorption co-
efficient µ and the externally measurable (but variable) body
thickness L. Sometimes e(µ/2)L is assumed to be constant so
that the activity Ai becomes proportional to NGMi . This as-
sumption may be valid, if only not much activity is taken
up by the extremities and by the lung and if the trunk is
regarded as being constantly thick.
In an alternate approach, e(µ/2)L can be determined by
transmission scans. The transmission scan should be per-
formed for every measurement. If it is only acquired once,
exact repositioning of the patient for all subsequent scans
is necessary. In order to simplify the procedure, relative at-
tenuation factors might be determined in some subjects by
transmission measurements using a flood source filled with
the appropriate radionuclide. Specific correction factors can
be obtained for head, neck, arms and legs as done by Krah-
winkel et al. [5]. These authors corrected for the inhomoge-
neous thickness of the trunk by assuming its cross section
to be elliptical. After calculation of the geometrically aver-
aged count rate in each pixel, the multiplicative corrections
are performed for the regions of trunk, arms, legs and tho-
rax. This provides a corrected count rate NGMC for each pixel
of the patient’s scan. This count rate is assumed to be pro-
portional to the activity underlying the single pixels [5]. The
activity AOrgan of a particular organ relative to the total body
activity ATotal is given by:
AOrgan = ATotal
∑
Organ NGMC∑
Total NGMC
(3)
∑
Organ
NGMC : Sum of corrected pixel count rates over
the organ of interest∑
Total
NGMC : Sum of corrected pixel count rates over
total body
At our centre this procedure was implemented in the study
of the biodistribution of 201Tl [5], 123I-heptadecanoic acid [6]
and 123I-α-methyltyrosine [1].
In the case of 201Tl, organs overlapping in the conjugate
views had to be taken into account: liver and right kidney or
stomach and left kidney, respectively. For this purpose an ad-
ditional correction procedure was developed which utilised
the low photon energy of 201Tl [4]. The method was vali-
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Organ Time after Injection (hours)
2 24 48 120 168 216
Whole-body 100 95.1±2.7 90.5±3.0 75.3±5.7 68.7±6.5 63.3±7.4
Brain 1.5±0.3 1.7±0.3 1.8±0.3 2.1±0.2 1.9±0.3 1.8±0.2
Facial part 3.1±0.5 3.2±0.4 3.2±0.5 2.9±0.4 2.7±0.5 2.3±0.3
Neck 1.2±0.2 1.2±0.1 1.1±0.1 0.9±0.1 0.8±0.2 0.7±0.2
Thyroid 0.5±0.1 0.5±0.1 0.5±0.1 0.4±0.1 0.3±0.1 0.3±0.1
Heart 3.9±0.9 2.9±0.6 2.6±0.4 2.1±0.3 1.8±0.3 1.5±0.4
Thorax (no heart) 6.2±0.6 6.1±0.5 5.8±0.6 4.7±0.6 4.1±0.6 3.5±0.7
Liver 5.1±0.7 4.1±0.5 3.8±0.3 3.1±0.4 2.7±0.3 2.4±0.3
Stomach 3.2±0.5 2.5±0.5 2.2±0.4 1.8±0.3 1.6±0.3 1.5±0.3
Spleen 1.0±0.2 0.9±0.1 0.8±0.1 0.7±0.1 0.6±0.1 0.6±0.1
Intestine 20.1±2.2 20.7±1.7 19.7±1.7 15.2±2.0 13.0±2.0 10.7±2.4
Kidneys 5.6±1.4 4.6±0.8 4.2±0.6 3.4±0.6 3.0±0.4 2.5±0.5
Arms 5.1±0.9 6.7±1.0 6.7±0.9 5.8±0.9 5.3±0.8 5.0±0.9
Legs 26.2±4.0 23.0±2.2 21.0±2.3 17.3±2.0 15.9±2.0 15.4±1.6
Thigh 18.2±2.4 15.0±1.5 13.2±1.6 10.5±1.4 9.5±1.3 9.3±0.9
Lower leg, foot 7.7±1.8 8.1±1.2 7.8±0.9 6.8±0.8 6.4±0.7 6.0±0.7
Femoral muscles 16.3±2.2 13.1±1.5 11.4±1.5 9.1±1.2 8.1±1.2 8.0±0.8
Tibia muscles 5.9±1.4 5.7±0.9 5.5±0.7 4.6±0.6 4.3±0.5 4.2±0.5
Testis (n=14) 0.4±0.1 0.3±0.1 0.3±0.1 0.3±0.1 0.3±0.1 0.3±0.1
Mean and standard deviation of the whole-body and relative organ activities in 15 patients
(Units are % injected activity, decay corrected)
Table 2. Biodistribution of 201Tl
(taken from [5]).
dated by three tests with an anthromorphologic whole-body
Alderson phantom applying different distributions of activ-
ity. In these tests, the errors were less than 14%, so the
biodistribution data for 201Tl shown in Table 2 and Fig. 2 can
be considered reasonably accurate.
Whole-body scans have to be done several times after
injection. The definite times must be chosen in respect to
the physical and biological decay of the radiopharmaceuti-
cal [7]. In the case of a very slow biological removal the
measurements should cover a period of up to 3 or 4 physi-
cal half-lives. Afterwards, the count rates become so low that
the statistical errors become considerable. If the measure-
ments cannot be extended so long, the measured data have to
be extrapolated until the physical decay of the radionuclide –
practically five half-lives as demonstrated below (Fig. 4).
Generally, it is possible to combine the whole-body
measurements with the diagnostic investigation, which is
commonly done shortly after the injection. After the diag-
nostic procedure whole-body scans can be done on the same
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Fig. 2. Time activity curves after the injection of 201Tl. The measured
decay-corrected radioactivity data are related to the amount of injected
radioactivity (= 100%).
day and if necessary during the following days. No addi-
tional radiation dose is received by the subject due to these
whole-body measurements; a relatively small dose results
from performance of a transmission scan.
Biodistribution measurement of positron
emitters
One of the main characteristics of PET is its ability to quan-
tify radioactivity within the body in absolute terms. There-
fore, diagnostic studies may supply biodistribution data as
well. This is especially true for oncological whole-body
studies such as those done with 18F-fluorodeoxyglucose
(FDG). These studies are, however, only quantitative if they
are corrected for attenuation with the help of additional
transmission scans. In order to know the biodistribution at
more than one time, it is necessary to repeat the whole-body
scans after an appropriate period. In the case of 18F-labelled
radiopharmaceuticals it may be sufficient to do 3 scans, e.g.
at 30–60 minutes, at 4 hours and at 6 hours after injection,
in this way covering three half-lives of the tracer. Uptake
data are obtained by defining regions of interest over the sin-
gle organs in all these transversal images in which the organ
is visible, so that the total activity within the organ as well
as the volume of the organ are obtained. The PET measure-
ment must be accompanied by measurements of excretion.
In most cases, it is sufficient to just measure the activity in
urine, as fecal elimination continues for a long time, over
which the radionuclide typically has decayed to negligible
levels. If the half-life of a positron emitter is longer than that
of 18F, as in the case of 86Y (T1/2 = 14.7 h), the whole-body
measurement must be repeated on a second or third day and
the necessity of measuring the feces must be checked.
If radiopharmaceuticals are labelled with short-lived ra-
dionuclides such as 11C or 15O, whole-body measurements
are no longer possible. Whole-body measurements may also
not be compatible with the diagnostic investigation of an
18F-labelled radiopharmaceutical, if a long static or dynamic
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Fig. 3. Schedule of transmission and emission scans over different or-
gans for the measurement of the biodistribution of the dopamine2
receptor ligand 18F-fluoro-ethyl-spiperone.
acquisition is needed in respect to one single organ. Then, it
may be sufficient to interrupt the diagnostic measurements
for 5 or 10 min and to do a quick scan over other organs
with possibly relevant uptake. By looking at one organ in
some patients and at other organs in different patients in-
tersubject uptake data are collected. An example of an ac-
quisition scheme which was performed for the 18F-labelled
D2-receptor ligand [18F]-fluoro-ethyl-spiperone is shown in
Fig. 3 [8].
Even in the case of the ultra-short lived radionuclide 15O
(T1/2 = 2.03 min) it was possible to obtain all biodistribu-
tion data relevant to dosimetry of 15O-butanol [9]. In this
case it was not possible to combine all necessary studies
with the diagnostic procedure so that some studies had to be
performed just for the measurement of the biodistribution.
However, only a small part of the activity used for the diag-
nostic procedure needed to be injected, so that the radiation
dose to those subjects volunteering for the biodistribution
measurements was kept very low.
In those cases where it is difficult to collect the necessary
biodistribution data – maybe because of the short half-life
of the tracer – model based analyses of biodistribution have
been suggested. Especially in the case of 15O-labelled wa-
ter, a number of models have been reported leading to quite
different radiation doses [10–13].
The unique ability of PET to quantify radioactivity can
also be exploited for the measurement of non-positron emit-
ting radionuclides. Many radionuclides used for diagnosis
and therapy in nuclear medicine have positron emitting ana-
logues so that PET can help to get quantitative biodistri-
bution data for those radiopharmaceuticals which are dif-
ficult to evaluate otherwise. This approach was first sug-
gested at Jülich for purely β−-emitting therapeutic radioiso-
topes [14]. Table 3 gives a list of radionuclides and their
positron emitting analogues. The only externally measur-
able radiation in case of pure β−-emitters is bremsstrahlung
yielding crude image information which is difficult to quan-
Table 3. Beta-emitters and their positron-emitting analogues.
β−-emitter β+-emitting analogue
Half-life Half-life β+-abundance
89Sr 50.4 d 83Sr 1.35 d 24%
90Y 3.19 d 86Y 14.7 h 33%
153Sm 1.95 d 142Sm 72 min 5.7%
131I 8.02 d 124I 4.18 d 63%
tify. The positron emitter 86Y was used to estimate the radi-
ation dose caused by some radiotherapeuticals labelled with
β−-emitting 90Y [14]. 86Y/90Y labelled citrate and EDTMP
were studied in patients suffering from prostate cancer to es-
timate the radiation dose caused by the 90Y-compounds to
normal tissue but also to metastases [15]. The biodistribution
of 86Y/90Y-DOTA-octreotide was investigated in baboons
to prepare the clinical trial phase II [16]. There are other
β−-emitters used for radiotherapy which emit γ -radiation
as well. Here conjugate whole-body imaging with whole-
body gamma cameras can and has been applied as described
above. On the other hand, the additional use of positron
emitting radioisotopes can improve the quantitative accuracy
of those whole-body measurements. For example, 124I might
be useful to calibrate analyses done with whole-body single
photon imaging or even SPECT studies [17].
Calculation of absorbed dose
Knowing the biodistribution of a radiopharmaceutical, i.e.
its distribution and biokinetics within the body, the estima-
tion of the radiation dose consists of knowing the energy
emitted along with the radiation and of determining that
part of this energy which is absorbed in the various tissues
of the body [18, 19]. Rarely does activity become taken up
by an organ and remain there with no biological removal.
Even in these cases, the activity diminishes with time, due to
physical decay of the radionuclide. In order to calculate the
radiation dose to the organ of uptake and other surrounding
tissues, one must count all of the decays of the nuclide over
time, from the moment of uptake until the final disappear-
ance of the nuclide, due to physical decay and/or biological
removal. The integral of the radioactivity A(t) over time rep-
resents all of the radioactive events that occurred within the
source organ:
A˜ =
∞∫
0
A(t)d t . (4)
The integral of radioactivity over time starting from the
injection up to the decay of the activity is called cumu-
lated activity A˜. The term decay is not only related to the
physical but also to the biological decay, i.e. the total elim-
ination of activity. To calculate the cumulated activity one
has to know the actual activity within a source organ as
a function of time. Here the time-activity curve should not
be decay-corrected. If, however, the cumulated activity has
been determined using a decay-corrected time-activity curve
the radioactive decay can be taken into account by the fol-
lowing equation
A˜ = A˜decay-corrected T1/2/ ln(2)= A˜decay-corrected1.443T1/2 , (5)
where T1/2 is the half-life, which relates to λphys, the physical
decay constant of the radionuclide, as follows
1/λphys = 1.443T1/2 . (6)
Often, the cumulated activity is related to the total admin-
istered activity Ao. In this case, the unit of radioactivity is
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cancelled out leaving an expression with the unit time. Al-
though not being a truly physical time, this entity is called
residence time τ .
τ = A˜/Ao . (7)
If Ai is a part of the total injected activity Ao and initially
taken up in organ i , from which it is released according to
a monoexponential outwash with a biological time constant
λbiol, the residence time τ can be calculated as follows
τ = 1/(λphys +λbiol)(Ai/Ao)= 1.443T eff1/2(Ai/Ao) (8)
T eff1/2 is the effective half-life indicating after which time half
of a radiopharmaceutical has left an organ by both physical
decay and biological removal.
Although the upper integration limit of (4) is infinity, ac-
tivity values may be available only over a relatively short
period. Therefore, A(t) has to be extrapolated beyond this
period. For this purpose the measured data may be fitted
using an appropriate function which is then extrapolated out
to several half-lives of the radionuclide. Fig. 4 shows fitted
curves found for a fictitious data set, of which the last data
point exhibits a 10% error, without and with decay correc-
tion. Curves corrected for decay showed a great uncertainty
due to this error, while curves including radioactive decay
all decrease rapidly, so that after five half-lives the residual
activity amounts only to 3% of the original activity at the
time of injection. The dominant role of the radioactive decay
makes an inaccuracy in the fitting and extrapolation process
less important.
Rarely do the measured values in all organs comprise
100% of the injected activity. Usually the most important
organs account for some percent of the total, and the re-
mainder is distributed more or less uniformly throughout all
other tissues. In this case, the MIRD formalism introduces
the concept of the remainder of the body. The remainder
of the body is the difference between the total administered
dose and the sum of all specifically known activities. The
remainder (activity) of the body is again a function of time
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Fig. 4. To calculate the cumulated activity the three data points have
to be extrapolated. Large differences result in the extrapolated curves
(black), due to the uncertainties of the last data point. This variance and
in this way the integral under the curves (cumulated activity) is consid-
erably decreased when the decay is taken into account (grey curves).
The decay corrected curves are very close to zero at five physical
half-lives of the radionuclide.
and its integral over time provides the cumulated activity or
residence time, respectively, of the remainder of the body.
In most applications, elimination from the body is primar-
ily by urinary excretion and secondarily, if at all, via the
fecal pathway. A proper balance of the biodistribution has
to include these pathways. For this purpose reliable excreta
measurements must be made. From this data the total activ-
ity remaining in the body can be calculated.
When the cumulated activities A˜j of all organs with rel-
evant uptake and of the remainder of the body have been
determined, the dose absorbed Di in these organs and in
other organs (targets) receiving radiation from the source or-
gans j can be calculated:
Di = Sij A˜j (9)
The so called S-factor represents the radiation dose received
in a target organ i per unit activity located in a source organ
j [18]. The target and source organ may be identical. The ra-
diation dose to an organ is the sum of all doses caused by the
activity in the organ itself and from all surrounding tissues:
Di =
∑
j
Sij A˜j (10)
The S-factor itself is a product of several entities according
to the following equation:
Sij = nE φij/mi (11)
where nE is the mean energy emitted per nuclear decay, φij
is the absorbed fraction (i.e. that part of the radiation en-
ergy emitted from source j which is absorbed in target i),
and mi is the mass of the target. The absorbed fraction is de-
pendent on the shape of the source and target organs and on
Table 4. Radiation dose from intravenous administration of 201Tl for
heart planar scintigraphy or SPECT.
Target organ Radiation Dose
n = 15 mGy/MBq mrad/mCi
Adrenals 0.011±0.002 0.039±0.007
Bladder wall 0.012±0.002 0.044±0.009
Bone 0.013±0.003 0.047±0.010
Heart 0.009±0.001 0.033±0.005
Small intestines 0.017±0.003 0.061±0.010
Upper large int. 0.070±0.020 0.260±0.075
Lower large int. 0.145±0.044 0.537±0.163
Kidney 0.064±0.011 0.236±0.040
Liver 0.015±0.002 0.054±0.008
Lungs 0.009±0.002 0.034±0.007
Red marrow 0.017±0.003 0.063±0.013
Muscle 0.009±0.002 0.034±0.007
Pancreas 0.013±0.003 0.049±0.010
Skin 0.007±0.001 0.025±0.005
Spleen 0.027±0.007 0.099±0.027
Stomach wall 0.028±0.007 0.105±0.026
Testes (n=14) 0.091±0.058 0.336±0.214
Thyroid 0.092±0.023 0.341±0.087
Uterus (n = 1) 0.015 0.050
Effective dose 0.096±0.047 0.356±0.176
equivalent mSv/MBq mrem/mCi
These results are based on the biodistribution data shown in Fig. 2
and Table 2
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Table 5. ICRP 26 [23]: Effective dose equivalent: HE =∑wi Di .
Tissue wi
Gonads 0.25
Breast 0.15
Red marrow 0.12
Lung 0.12
Thyroid 0.03
Bone surfaces 0.03
Remainder 0.30
Remainder: Assign a weight of 0.06 to each 5 organs of the
remainder with the highest Di .
the distance between them, as well as on the structures of
other tissues situated between the source and target. For γ -
radiation φ is less than one, whereas for β-radiation, which
is assumed not to escape the source, φ is equal to one [19].
For diagnostic purposes, it is not feasible to use S-factors
for an individual patient. Instead S-factors are based on the
geometrical relationship which have been defined for a hu-
man standard phantom [18, 20]. In order to estimate the dose
caused by an individual radionuclide therapy, the target mass
and the source-target relationship should be derived from the
patient-specific geometry obtained from computed tomogra-
phy or magnet resonance imaging [21].
Knowing the cumulated activities of all single source
organs and of the remainder of the body the doses ab-
sorbed by the target organs (including the total body) can
be calculated, resulting in a table such as shown in Table 4.
Table 7. Some commonly used SPECT and PET radiopharmaceuticals and the resulting effective doses.
Radiopharmaceutical Function Effective dose equivalent Effective Dose Reference
(mSv/MBq) (mSv/MBq)
Used for SPECT
99mTc-HMPAO Brain blood flow 0.012 [27]
99mTc-ECD Brain blood flow 0.008 [28]
99mTc-sestamibi Heart blood flow 0.004 [29]
99mTc-tetrofosmin Heart blood flow 0.0089 [30]
99mTc-DMSA Renal function 0.005 [31]
99mTc-TRODAT Dopamin-transporter 0.015 0.012 [32]
111In-DTPA-D-Phe-1-octreotide Somatostatin receptor ligand 0.080 [33]
111In-pentetreotide Somatostatin receptor ligand 0.100 0.073 [34]
123I-IMP Brain blood flow 0.024 [35]
123I-IBZM Dopamin2-receptor-ligand 0.034 [36]
123I-iomazenil Benzodiazepine receptor ligand 0.033 [37]
123I-epidepride Dopamin2-receptor-ligand 0.035 [38]
123I-ß-CIT Dopamin-transporter 0.024 [39]
131I-IgM Immunoscintigraphy 0.120 [40]
191mIr Blood flow 0.004 [41]
201Tl Heart blood flow 0.096 [4]
Used for PET
11C-N-methylspiperone Dopamin2-receptor-ligand 0.007 [42]
11C-raclopride Dopamin2-receptor-ligand 0.003 [43]
11C-iomazenil Benzodiazepine receptor ligand 0.015 [44]
11C-glucose Glucose metabolism 0.004 m/0.005 f [45]
11C-methionine Amino acid tracer 0.0052 [46]
11C-acetate Heart oxygen metabolism 0.004 [42]
13N-ammonia Heart blood flow 0.003 [42]
15O-water Blood flow 0.001 0.001150 [12]
18F-FDG Glucose metabolism 0.019 [42]
18F-L-dopa Dopamin-pool 0.018 [47]
18F-fluoromisonidazole Hypoxia marker 0.013m/0.014f [48]
Table 6. ICRP 60 [34]: Effective dose: HE =∑wi Di .
Tissue wi
Gonads 0.20
Colon 0.12
Red morrow 0.12
Lung 0.12
Stomach 0.12
Bladder 0.05
Breast 0.05
Liver 0.05
Oesophagus 0.05
Thyroid 0.05
Skin 0.01
Bone surfaces 0.01
Remainder 0.05
Remainder: Assign a weight of 0.05 to the mean dose of adrenals,
brain, upper large intestine, small intestine, kidney, muscle, pancreas,
spleen, thymus, and uterus.
Some years ago, Stabin [22] has published a very valuable
program called MIRDOSE (present version MIRDOSE3)
which requires the residence times as input data, contains
S-factors of numerous radionuclides, and yields a list of ra-
diation doses to single organs as well as the whole-body
dose according to ICRP 26 [23] and ICRP 60 [24], respec-
tively (see below). The MIRDOSE3 program also includes
the specific considerations necessary for calculating the ra-
diation dose of the urinary bladder and the gastro-intestinal
tract. The estimation of the bladder dose applies the sugges-
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tion of Cloutier and coworkers [25], for which the voiding
interval is an important variable.
To our knowledge, there has been no unified tool which
offers the fitting and extrapolation of the measured time-
activity data, the calculation of the cumulated activities as
well as the calculation of the radiation doses for the single
organs and the total body. Therefore, our group developed
an Excel program which combines all these steps so that the
whole procedure is considerably facilitated [26].
In order to characterise the amount of radiation dose
and in this way also the risk caused by a specific nuclear
medicine procedure, previous papers reported the highest of
all single organ doses and the dose to the total body. The
organ with the highest dose was called critical organ.
This approach, however, does not take into account that
some organs are more radiation-sensitive than others. There-
fore, ICRP 26 has also considered the radiobiological sen-
sitivity of different organs in respect to the ionising ra-
diation. For this purpose the radiation dose caused to the
whole-body dose is described by the so-called effective
dose equivalent (HE), which is a weighed sum of the radia-
tion doses primarily to those organs which are regarded as
radiation-sensitive.
HE =
∑
wi Di (12)
This formula is valid for X-rays, γ - and β-radiation. The
suggestions of ICRP 26 [23] have been revised by ICRP
60 [24] which replaced the term effective dose equivalent
by the effective dose and modified the weighting factors wi .
Tables 5 and 6 display the weighting factors as suggested by
ICRP 26 and ICRP 60. Although ICRP 60 is the up-to-date
international recommendation, national rules and dose limits
are partly still based on ICRP 26.
Radiation doses in SPECT and PET studies
Table 7 presents the data of the effective dose equivalent
and effective dose, respectively, caused by commonly used
SPECT and PET radiopharmaceuticals.
In order to compare these values they must be multiplied
with the amount of radioactivity which has to be adminis-
tered to assure a satisfactory image quality needed for diag-
nosis or scientific evaluation. In general, the dose to a patient
must be judged in relation to the expected benefit by the
SPECT or PET examination, whereas the dose to volunteers
is limited by national regulation.
Concluding remark
This paper presents a review of in vivo methods to obtain the
biodistribution of radiopharmaceuticals used with SPECT
and PET as well as the description of dosimetric calcula-
tions. The interested reader will find more detailed informa-
tion about these issues in some recent articles and MIRD
reports [7, 49–51].
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